Amgen gets buy rating from Jefferies

Jefferies & Co., Inc. analyst Adam Walsh gave Amgen, Inc. a buy rating on forecasts of fourth-quarter 2005 total revenue of $3.3 billion and earnings per share of 0.76, in line with street consensus. Legal issues surrounding Roche's CERA could put a ceiling on the stock. Amgen will report fourth-quarter 2005 earnings on Thursday. Shares of the Thousand Oaks, Calif., biotechnology company were up 53 cents, or 0.71%, at $5.47 on volume of 8,301,049 shares versus the three-month running average of 7,186,510 shares. (Nasdaq: AMGN)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.